Sign in Subscribe

preclinical

A collection of 65 issues

Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC

Skip to content The CRC Digest ◇ RESEARCH Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials) This content is informational only

HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer

Skip to content The CRC Digest HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology) This content is informational only and does not constitute

Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC Researchers used single-cell RNA sequencing to compare PD-1-resistant and PD-1-sensitive MSI-H metastatic colorectal tumors, identifying a gene regulatory network involving ETV4 and MC1R that may explain why some MSI-H cancers don'

CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells

Skip to content The CRC Digest ◇ RESEARCH CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences) This content

Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models

Skip to content The CRC Digest ◇ RESEARCH Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The

Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Discoidin Domain Receptor 1 promotes collagen alignment and immune exclusion in microsatellite stable colorectal cancer (Cancer Res Commun) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells

Skip to content The CRC Digest Plant-derived formulation disrupts metabolism in KRAS-mutant colorectal and pancreatic cancer cells A Lepidium latifolium formulation induced cell death and metabolic disruption in KRAS-mutant cancer models through iron-dependent mechanisms. (Molecules) This content is informational only and does not constitute medical advice. Always consult your oncologist

Study evaluates potential hearing damage from oxaliplatin in preclinical model

Skip to content The CRC Digest ♥ LIVING WITH CRC Study evaluates potential hearing damage from oxaliplatin in preclinical model Mouse study evaluated potential hearing damage induced by oxaliplatin. (Hearing Research) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models

Skip to content The CRC Digest Targeted m6A Demethylation of ZBTB7A Suppresses Liver Metastasis in Preclinical Models Researchers identified ZBTB7A as an m6A-modified transcription factor that promotes colorectal cancer liver metastasis, with METTL3-mediated m6A modification of ZBTB7A facilitating recognition by the m6A reader YTHDF1/3 complex. (Molecular Cancer) This content